Discussion Highlights Twice-Yearly HIV PrEP Injection

- Lenacapavir is a first-in-class HIV-1 capsid inhibitor, meaning it uses a new mechanism of action not seen in previous antiretroviral drugs. It works by interfering with the HIV-1 capsid, a protein shell that protects the virus's genetic material, at multiple stages of the viral lifecycle. - The drug, marketed as Yeztugo for PrEP, was approved by the U.S. Food and Drug Administration (FDA) in June 2025 for adults and adolescents weighing at least 35kg. This approval was based on two major clinical trials, PURPOSE 1 and PURPOSE 2, which were stopped early due to the drug's high efficacy. - The PURPOSE 1 trial, conducted with over 5,300 young women in South Africa and Uganda, showed 100% efficacy, with no participants in the lenacapavir group acquiring HIV. The PURPOSE 2 trial included cisgender men, transgender men and women, and gender non-binary individuals, and demonstrated that 99.9% of participants receiving the injection did not contract HIV. - The development of a drug like lenacapavir involves a wide range of careers. Computational biologists and bioinformaticians use programming and data analysis to identify potential drug targets and analyze vast biological datasets. Their work is largely research-focused and involves coding, developing algorithms, and managing large-scale data on computer clusters. - On the other hand, patient-facing roles are crucial for clinical trials. Clinical research physicians, who need a medical degree and several years of clinical practice, oversee these trials, ensure patient safety, and manage the study protocol. They work directly with trial participants, alongside a team that can include study coordinators and nurses. - The journey to becoming a clinical research physician is lengthy, typically requiring a bachelor's degree, four years of medical school, and three to seven years of residency before gaining clinical experience. In contrast, a career in bioinformatics or computational biology often requires a bachelor's or master's degree in a field that combines biology and computer science, with many roles in the pharmaceutical industry preferring a Ph.D. - Following its approval, efforts are underway to make lenacapavir accessible globally. Partnerships have been established to produce generic versions of the drug for 120 low- and middle-income countries at a significantly reduced price. However, challenges remain in securing regulatory approval in all countries and ensuring healthcare systems are equipped for its administration.